{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:26:01Z","timestamp":1761888361347,"version":"build-2065373602"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Neuroendocrine neoplasms are heterogeneous tumours arising from endocrine gland cells and the neuroendocrine system. Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) constitute two-thirds of this tumour group. This study was aimed at investigating the relationship between histone deacetylase enzymes (HDAC) and glutamine synthetase (GS) positivity, and 68Ga-DOTATATE PET\/CT data and their effect on prognosis in gastroenteropancreatic neuroendocrine tumours. Materials and Methods: Twenty-seven patients with Grade 1 and Grade 2 well-differentiated neuroendocrine tumours, diagnosed by biopsy and admitted to our nuclear medicine clinic for staging were included in the study. Results: There was no statistically significant correlation between HDAC and GS positivity in tumours and DOTATATE SUVmax value on PET\/CT. There was no significant correlation between HDAC and GS positivity or negativity in the tumour and the presence or absence of metastasis on PET\/CT. There was no statistically significant relationship between HDAC and GS positivity and survival. There was a statistically significant correlation between DOTATATE SUVmax value on PET\/CT and survival (p = 0.039). Conclusions: According to the results of the present study, overall survival rates decreased in patients with high 68Ga-DOTATATE uptake on PET\/CT and therefore, patients with high SUVmax on PET\/CT should be followed closely and their prognosis may be poor. In addition, although not statistically significant, the mortality rate is higher in patients with HDAC-positive tumours compared to in patients with HDAC-negative tumours; thus, it should be kept in mind that the prognosis of such patients may also be poor. According to the results of the present study, GS levels were generally negative in NETs. In addition, there was no statistically significant relationship between GS levels and survival.<\/jats:p>","DOI":"10.3390\/medicina61111952","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:48:28Z","timestamp":1761878908000},"page":"1952","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are HDAC and Glutamine Synthetase Expression Levels Associated with Ga68-DOTATATE PET\/CT Data and Prognosis in Gastroenteropancreatic Neuroendocrine Tumours?"],"prefix":"10.3390","volume":"61","author":[{"given":"Ozge","family":"Ulas","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Tokat Gaziosmanpasa University, Tokat 60250, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan Oguz","family":"Yuceer","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekiye","family":"Hasbek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice","family":"Ozer","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1683-1776","authenticated-orcid":false,"given":"Kerim","family":"Seker","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukaddes","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Oncology, School of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"U\u00e7ar","sequence":"additional","affiliation":[{"name":"Department of Oncology, School of Medicine, Sivas Cumhuriyet University, Sivas 58140, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: Are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tan, B., Zhang, B., and Chen, H. (2024). Gastroenteropancreatic neuroendocrine neoplasms: Epidemiology, genetics, and treatment. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1424839"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","article-title":"ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and prognostic stratification","volume":"105","author":"Perren","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/jnci\/djn275","article-title":"Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine Tumors","volume":"100","author":"Modlin","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0968-0004(00)01718-7","article-title":"25 years after the nucleosome model: Chromatin modifications","volume":"25","author":"Wu","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Lane","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., and Newsholme, P. (2018). Glutamine: Metabolism and immune function, supplementation and clinical translation. Nutrients, 10.","DOI":"10.20944\/preprints201809.0459.v1"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kim, G.W., Lee, D.H., Jeon, Y.H., Yoo, J., Kim, S.Y., Lee, S.W., Cho, H.Y., and Kwon, S.H. (2021). Glutamine Synthetase as a Therapeutic Target for Cancer Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041701"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1152\/ajplegacy.1969.216.5.1107","article-title":"Glutamine synthetase and renal ammonia metabolism","volume":"216","author":"Janicki","year":"1969","journal-title":"Am. J. Physiol.-Leg. Content"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","article-title":"Fundamentals of cancer metabolism","volume":"2","author":"DeBerardinis","year":"2016","journal-title":"Sci. Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: A hallmark of cancer metabolism","volume":"19","author":"Yang","year":"2017","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1038\/onc.2015.447","article-title":"Glutaminolysis as a target for cancer therapy","volume":"35","author":"Jin","year":"2016","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kung, H.N., Marks, J.R., and Chi, J.T. (2011). Glutamine synthetase is a genetic determinant of cell type\u2013specific glutamine independence in breast epithelia. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1002229"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4132\/KoreanJPathol.2012.46.4.311","article-title":"HDAC1 expression in invasive ductal carcinoma of the breast and its value as a good prognostic factor","volume":"46","author":"Eom","year":"2012","journal-title":"Korean J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Takahashi, Y., Dungubat, E., Kusano, H., Ganbat, D., Tomita, Y., Odgerel, S., and Fukusato, T. (2021). Application of immunohistochemistry in the pathological diagnosis of liver tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115780"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: A new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wanek, J., Gaisberger, M., Beyreis, M., Mayr, C., Helm, K., Primavesi, F., and Kiesslich, T. (2018). Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103128"},{"key":"ref_23","first-page":"545","article-title":"HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II","volume":"10","author":"Sun","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","article-title":"Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide\u2013drug conjugate via activating somatostatin receptor type II","volume":"24","author":"Sun","year":"2016","journal-title":"J. Drug. Target."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.surg.2019.05.092","article-title":"Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment","volume":"167","author":"Guenter","year":"2020","journal-title":"Surgery"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Klomp, M.J., Dalm, S.U., van Koetsveld, P.M., Dogan, F., de Jong, M., and Hofland, L.J. (2021). Comparing the effect of multiple histone deacetylase inhibitors on SSTR2 expression and [111In] in-DOTATATE uptake in NET cells. Cancers, 13.","DOI":"10.3390\/cancers13194905"},{"key":"ref_27","first-page":"632","article-title":"Potential for increasing uptake of radiolabeled 68Ga-DOTATOC and 123I-MIBG in patients with midgut neuroendocrine tumors using a histone deacetylase inhibitor vorinostat","volume":"36","author":"Pollard","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40618-025-02552-1","article-title":"Clinical and biological heterogeneity of Grade 2 digestive neuroendocrine neoplasms: Prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies. A longitudinal study","volume":"48","author":"Massironi","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1002\/ctm2.957","article-title":"Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients","volume":"12","author":"Refardt","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jcp.1030640211","article-title":"The intracellular distribution of glutamine synthetase in rat liver and the effect of metals on its activity","volume":"64","author":"Hsu","year":"1964","journal-title":"J. Cell Comp. Physiol."},{"key":"ref_31","first-page":"1115","article-title":"Effects of methionine sulfoximine analogs on the synthesis of glutamine and glutathione: Possible chemotherapeutic implications","volume":"63","author":"Meister","year":"1979","journal-title":"Cancer Treat. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.1093\/nar\/15.15.6293","article-title":"Sequence of a human glutamine synthetase cDNA","volume":"15","author":"Gibbs","year":"1987","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0148607191015002159","article-title":"Tumor regulation of hepatic glutamine metabolism","volume":"15","author":"Chen","year":"1991","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000658-199306000-00007","article-title":"Influence of progressive tumor growth on glutamine metabolism in skeletal muscle and kidney","volume":"217","author":"Chen","year":"1993","journal-title":"Ann. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7290-2014","DOI":"10.2310\/7290.2014.00048","article-title":"[13N] Ammonia positron emission tomographic\/computed tomographic imaging targeting glutamine synthetase expression in prostate cancer","volume":"14","author":"Shi","year":"2015","journal-title":"Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ippolito, J.E., and Piwnica-Worms, D. (2014). A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088667"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Castegna, A., and Menga, A. (2018). Glutamine synthetase: Localization dictates outcome. Genes, 9.","DOI":"10.3390\/genes9020108"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1952\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:42:36Z","timestamp":1761882156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111952"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111952","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}